Minimally Invasive Nasal Trabeculostomy: Long-Term Follow-Up Extension Study
Completed
- Conditions
- Open Angle Glaucoma
- Registration Number
- NCT06612346
- Lead Sponsor
- Sanoculis Ltd
- Brief Summary
This study is a follow-up extension study conducted in continuation of the prior MINT study (MMS-EEU-4), in which the long-term (i.e., 18, 24 months) clinical outcomes of Minimally Invasive Nasal Trabeculostomy (MINT) will be explored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Male or female ≥ 18 years to ≤ 85 years old
- Subject who underwent MINT, and surgery was performed not earlier than 18 months from enrollment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intraocular Pressure Measurement 18 months +/- 2 months post-MINT surgery from previous study (MMS-EEU-4). Observed IOP at long-term timepoints
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term efficacy outcomes of Minimally Invasive Nasal Trabeculostomy in open-angle glaucoma patients compared to traditional trabeculectomy?
How does the MINT device mechanism of action compare to other minimally invasive glaucoma surgery (MIGS) devices like iStent or XEN Gel Stent in terms of intraocular pressure reduction?
What biomarkers are associated with successful aqueous humor outflow following micro trabeculostomy procedures in primary open-angle glaucoma?
What are the most common adverse events reported in MINT procedure clinical trials and how do they compare to standard glaucoma filtration surgeries?
How does the long-term safety profile of Sanoculis' MINT device compare to other investigational glaucoma drainage devices in phase 2/3 trials?
Trial Locations
- Locations (1)
S. Malayan Eye Center
🇦🇲Yerevan, Armenia
S. Malayan Eye Center🇦🇲Yerevan, Armenia